MDCX Medicus Pharma Ltd.
Listings ·
Nasdaq closed Medicus Pharma's bid price case on October 23, 2026, three days after a delisting letter. The 8-K does not say whether the company now meets the $5 million stockholders' equity standard Nasdaq cited.
The lender paid $12 million at closing and deposited $10 million in a subsidiary's account under a deposit account control agreement. The notes carry monthly cash redemptions and trigger-based increases.
Medicus Pharma (Nasdaq: MDCX) sold shares in eight transactions between September 8 and October 16, 2025 for approximate aggregate consideration of $2,526,364. It used part to prepay a Yorkville debenture.
The 8% debenture matures in twelve months and refinances about $1.7 million of earlier Yorkville debentures. Medicus expects net proceeds of approximately $5.7 million, and the lender can require repayment from part of any equity raise.
Medicus closed its Antev deal on August 29, 2025 and could owe up to approximately $65 million more on milestones. It also sold 250,000 shares to Yorkville for approximately $490,535 and added Patrick J. Mahaffy to its board.
Antev shareholders would receive about 17% of Medicus common shares, plus up to US$65 million in contingent payments tied to FDA milestones. Antev's lead drug missed a secondary endpoint in an earlier Phase 2a trial, and Medicus carries going-concern doubt.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $7.7 million | $3.5 million |
| Net income (loss) | -$47.3 million | -$11.2 million |
| Cash from operations | -$22.8 million | -$10.2 million |
| Cash and equivalents | $8.7 million | $4.2 million |
Our latest story on this, dated Oct 23, 2026: "Medicus Pharma regains Nasdaq $1.00 bid price compliance days after delisting letter". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 30, 2025: "Medicus Pharma agrees to buy Antev for 2,666,600 shares plus up to US$65 million". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 30, 2025: "Medicus Pharma agrees to buy Antev for 2,666,600 shares plus up to US$65 million". The story links the filing or release it is based on. Read the story.
Medicus Pharma Ltd. trades under the ticker MDCX on NASDAQ.
Medicus Pharma Ltd. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Medicus Pharma Ltd. is 1997296. Its filings are on SEC EDGAR.
63,180,610 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-12.
Our directory records Medicus Pharma Ltd. under Canada.
Our directory classifies Medicus Pharma Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Medicus Pharma Ltd. is CA58471K3010.
aibio.space lists Medicus Pharma Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as A6.
Medicus Pharma Ltd. reported a net loss of $47.3 million for the fiscal year ended Dec 31, 2025, and used $22.8 million of cash in operations, per its annual report to the SEC.
$7.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
$15.2 million in cash at Jun 30, 2026, per its 10-Q.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,2.03,3.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,3.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,8.01,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,3.02,5.02,8.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.07,8.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,9.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported a financing. SEC Form S-1. Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Reported a reverse stock split. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio